Tulane Research and Innovation for Arrhythmia Discoveries- TRIAD Center, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.
Department of Biomedical Engineering, Johns Hopkins University, 733 N Broadway, Baltimore, MD 21205, USA.
Europace. 2023 Mar 30;25(3):889-895. doi: 10.1093/europace/euad018.
The aim of our study was to assess differences in post-ablation atrial fibrillation (AF) recurrence and burden and to quantify the change in LVEF across different congestive heart failure (CHF) subcategories of the DECAAF-II population.
Differences in the primary outcome of AF recurrence between CHF and non-CHF groups was calculated. The same analysis was performed for the three subgroups of CHF and the non-CHF group. Differences in AF burden after the 3-month blanking period between CHF and non-CHF groups was calculated. Improvement in LVEF was calculated and compared across the three CHF groups. Improvement was also calculated across different fibrosis stages. There was no significant differences in AF recurrence and AF burden after catheter ablation between CHF and non-CHF patients and between different CHF subcategories. Patients with heart failure with reduced ejection fraction (HFrEF) experienced the greatest improvement in EF following catheter ablation (CA, 16.66% ± 11.98, P < 0.001) compared to heart failure with moderately reduced LVEF, and heart failure with preserved EF (10.74% ± 8.34 and 2.00 ± 8.34 respectively, P-value < 0.001). Moreover, improvement in LVEF was independent of the four stages of atrial fibrosis (7.71 vs. 9.53 vs. 5.72 vs. 15.88, from Stage I to Stage IV respectively, P = 0.115).
Atrial fibrillation burden and recurrence after CA is similar between non-CHF and CHF patients, independent of the type of CHF. Of all CHF groups, those with HFrEF had the largest improvement in LVEF after CA. Moreover, the improvement in ventricular function seems to be independent of atrial fibrosis in patients with persistent AF.
本研究旨在评估消融术后心房颤动(AF)复发和负荷的差异,并量化 DECAAF-II 人群不同充血性心力衰竭(CHF)亚组的左心室射血分数(LVEF)变化。
计算 CHF 组和非 CHF 组之间主要结局(AF 复发)的差异。对 CHF 亚组和非 CHF 组进行了相同的分析。计算 CHF 组和非 CHF 组之间 3 个月空白期后 AF 负荷的差异。计算 LVEF 在三个 CHF 组中的改善情况并进行比较。还计算了不同纤维化阶段的改善情况。CHF 组和非 CHF 组之间以及不同 CHF 亚组之间,导管消融后 AF 复发和 AF 负荷无显著差异。与中度射血分数降低的心力衰竭和射血分数保留的心力衰竭相比,射血分数降低的心力衰竭(HFrEF)患者在导管消融后 EF 改善最大(CA,16.66%±11.98,P<0.001)。分别为 10.74%±8.34%和 2.00±8.34%,P 值<0.001)。此外,LVEF 的改善与心房纤维化的四个阶段无关(分别从 I 期到 IV 期为 7.71%、9.53%、5.72%和 15.88%,P=0.115)。
CA 后 AF 负荷和复发在非 CHF 患者和 CHF 患者之间相似,与 CHF 类型无关。在所有 CHF 组中,HFrEF 患者在 CA 后 LVEF 改善最大。此外,在持续性 AF 患者中,心室功能的改善似乎与心房纤维化无关。